ABSTRACT. The physiologic role of endothelin-1 (ET-1) and its receptors in regulating fetal pulmonary vascular tone is unknown. We therefore investigated the role of ET-1 and its receptors in the regulation of fetal pulmonary vascular tone using BQ 123 (an ET, receptor antagonist) and 4 Ala ET-1 (an ETb receptor agonist). In six fetal sheep in utero, we found that injections of ET-1 (250 ng/ kg fetal weight) into the left pulmonary artery increased left pulmonary blood flow (21.0 f 17.5 to 74.7 f 32.9 mL/ kg/min, p < 0.05) and decreased left pulmonary vascular resistance (6.02 f 7.00 to 0.84 f 0.48 mm Hg/kg/min/mL, p c 0.05). BQ 123 (5 mg) increased pulmonary blood flow (24.6 f 28.7 to 47.7 f 27.4 mL/kg/min, p < 0.05) and 1 1, 18) . We have previously shown that BQ 123 is a selective ET, antagonist in newborn lambs and inhibits ET-I-induced pulmonary vasoconstriction (8). In contrast to BQ 123,4 Ala ET-1 is a selective ETh agonist that induces pulmonary vasodilation during U44619-induced pulmonary hypertension ( 18).
receptors are thought to be located on the vascular smooth muscle, and their mechanism of action is unknown (1 [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] .
Recently, potent, selective ET-I receptor subtype antagonists and agonists have been developed. BQ 123 [Cyclo (D-ASPL-Pro-D-Val-L-Leu-D-Trp), Peptides International, Louisville, KY], a cyclic pentapeptide, is a potent ET, receptor antagonist (6) (7) (8) . In contrast, 4 Ala ET-I (Ala','.' '.Is ET-I , Parke-Davis, Ann Arbor, MI) is a potent ETh receptor agonist (10, 1 1, 18). We have previously shown that BQ 123 is a selective ET, antagonist in newborn lambs and inhibits ET-I-induced pulmonary vasoconstriction (8) . In contrast to BQ 123,4 Ala ET-1 is a selective ETh agonist that induces pulmonary vasodilation during U44619-induced pulmonary hypertension ( 18).
This study had two main objectives. The first was to investigate the role of ET-I and its receptors in the regulation of pulmonary vascular tone in near-term, chronically instrumented fetal sheep in tttero by studying the effects of a selective ET-I receptor antagonist and agonist. The second objective was to investigate the mechanism of the ET-I effect on the pulmonary circulation. For the first objective, we studied the effects of injections of ET-1 and 4 Ala ET-I into the left pulmonary artery and inferior vena cava and infusions of BQ 123 into the left pulmonary artery on fetal pulmonary vascular tone. For the second objective, we compared the hemodynamic effects of exogenous ET-1 before and during the infusion of glibenclamide (an ATP-dependent potassium channel blocker).
MATERIALS AND METHODS

Sztrgical preparation.
Fetal surgery was performed as previously described (19). Briefly, a total of six Western fetal sheep were studied at 135.8 k 6.1 d gestational age (term 145 d). The ewe was anesthetized with an epidural injection of 4 mL of I % tetracaine hydrochloride. Polyvinyl catheters were inserted into the maternal pedal vein and artery after local infiltration with 2% lidocaine hydrochloride.
With use of aseptic techniques, the uterus was exposed through a midline incision. Through a small uterine incision the hind limb was exposed, and polyvinyl catheters were inserted into the fetal wdal vein and artery and their tips advanced to the descend-artery and vein and their tips advanced to the ascending aorta and right atrium, respectively. The pericardium was incised along the main pulmonary trunk. ET-I may constrict the ductus arteriosus and thereby influence pulmonary blood flow (20, 2 1); therefore, to prevent ductus vasoreactivity during subsequent pharmacologic studies, the ductus arteriosus was visualized and the adventitia infiltrated with 10% formalin colored with a few drops of sterile methylene blue solution. Three Teflon cannulas attached to polyvinyl catheters were then inserted, one into the main pulmonary trunk, one directly into the left pulmonary artery (tip pointing toward the lung, positioned about 1 cm beyond the main pulmonary artery bifurcation), and one into the left atrium. A 4-mm ultrasonic flow transducer (Transonic Systems, Inc., Ithaca, NY) was placed around the left pulmonary artery to measure left pulmonary arterial blood flow. The thoracotomy incision was closed in layers. Warm saline was infused to replace the lost amniotic fluid, and the uterine incision was closed. A 12 French chest tube was placed in the amniotic cavity. The catheters were filled with heparin sodium, plugged, and brought to the skin along with the transducer cable, where they were protected in a pouch secured to the ewe's flank. After recovery from anesthesia, the ewe was returned to the cage. At least 2 d were allowed for recovery. Daily, I million U of penicillin G procaine and 100 mg of gentamicin suspension were administered to the ewe and also into the amniotic cavity. All protocols were approved by the Committee on Animal Research of the University of California, San Francisco.
Drug preparation. ET-1 (0.5 mg) (Peptides International, Inc.) was resuspended in 10 mL of sterile water and stored at -20°C. BQ 123 (5 mg) (Peptides International Inc.) was resuspended in I M sodium bicarbonate to a final concentration of I mg/mL. The 4 Ala ET-I (Ala','.' '.I5 ET-I, Parke-Davis) was resuspended in 2% DMSO-sterile water. Immediately before administration, each dose of ET-I and 4 Ala ET-I was measured and diluted to I mL with 0.9% saline. Cromakalim (Smith Kline Beecham Pharmaceuticals, Surrey, England) was dissolved in 0.9% saline. Glibenclamide (Glybenclamide, Sigma Chemical Co., St. Louis, MO) was dissolved in sterile water and titrated to pH 12.0 with the addition of I N NaOH. All solutions were prepared on the day of the study and kept on ice until administered.
Experimental protocol. In six chronically instrumented fetal sheep, we studied the hemodynamic effects of injections of ET-1 and 4 Ala ET-I into the left pulmonary artery and inferior vena cava and of infusions of BQ 123 into the left pulmonary artery. The route of administration and the drug for administration were randomly selected. Pulmonary artery and inferior vena cava injections were studied to assess possible differential hemodynamic effects secondary to the route of administration. In five of these six fetal sheep, after allowing a 24-h recovery period, we studied the hemodynamic effects of injections of ET-I into the left pulmonary artery before and during glibenclamide (an ATPdependent potassium channel blocker) infusion. The doses of ET-I, 4 Ala ET-1, cromakalim (an ATP-dependent potassium channel activator), and glibenclamide were based on the estimated weight of the fetus at time of surgery (3.17 ? 0.4 1 kg); the actual weight at autopsy was 2.75 + 0.48 kg.
ET-I and 4 Ala ET-I injections. The fetal sheep was studied with the ewe standing quietly in a study cart with free access to food and water. Succinylcholine hydrochloride (20 mg) was given for muscle relaxation to prevent fetal movements. Baseline measurements of the hemodynamic variables (pulmonary arterial blood pressure, left pulmonary arterial blood flow, systemic arterial blood pressure, heart rate, left and right atrial pressures, and amniotic fluid pressure) and systemic arterial blood gases and pH were measured. ET-l (250 ng/kg), 4 Ala ET-l ( 1725 ng/ kg), or their vehicles, 0.9% saline or 2% DMSO, were then injected into the left pulmonary artery or inferior vena cava in random order. Previously, we found that these doses, administered in bolus injections, produced reproducible, potent, yet short-term pulmonary vasodilation in newborn lambs (4, 18) .
The short duration of effect allowed repeated testing of these difficult preparations. Each agent was injected over 10 s, followed by a 2-mL flush of 0.9% saline. The hemodynamic variables were monitored continuously and measured at the point of maximum change in left pulmonary arterial blood flow (ET-I and 4 Ala ET-I). Systemic arterial blood gases and pH were measured 15 min after injections of ET-I or 4 Ala ET-1 into the left pulmonary artery. At least 60 min were allowed between each injection for all hemodynamic variables to return to preinjection values. All measurements were then repeated, and another agent was given.
Infusions of BQ 123 into the It$ pulmonary artery. Baseline measurements of the hemodynamic variables and systemic arterial blood gases and pH were measured. BQ 123 (5 mg) or sodium bicarbonate (drug vehicle) (5 mEq) in random order was then infused into the left pulmonary artery over 5 min. The hemodynamic variables were measured 5 and 10 min after the start of the infusion, and systemic arterial blood gases and pH were measured 5 min after the start of the infusion. Previously, we found that this dose of BQ 123 inhibited pulmonary vasoconstriction induced by ET-1 in lambs (8) .
ET-I injections during glibenclamide infusion. After a 24-h recovery period, five of the six fetal sheep could be studied again. Baseline measurements of the hemodynamic variables, systemic arterial blood gases, and pH were made. Then ET-I (250 ng/kg) or cromakalim (50 pglkg; a potassium channel activator) was injected in random order into the left pulmonary artery. All variables were measured at the point of maximal left pulmonary arterial blood flow effect. Systemic arterial blood gases and pH were measured 15 min after the injection of the agent. At least 60 min were allowed between injections for all variables to return to preinjection values. One hour after the second injection, when all variables had returned to baseline, glibenclamide (0.7 mg/kg/ min), an ATP-gated potassium channel blocker, was infused into the left pulmonary artery. After 15 min, while the glibenclamide infusion continued, all variables were again measured to evaluate the effects of glibenclamide alone on these variables. Thereafter, the injections of ET-I or cromakalim were repeated (in the presence of glibenclamide) and all variables were again measured as described above. Responses to the injections of ET-1 or cromakalim during glibenclamide infusion were evaluated by comparing the measurements obtained at maximal effect with those obtained immediately before the injection of ET-I or cromakalim. Previous studies from our laboratories (19) have shown that in these volumes the i.v. infusion of distilled water (pH 12) did not change the hemodynamic variables or the responses to ET-I or cromakalim.
At the end of the study, the ewes were given a lethal dose of pentobarbital sodium, then the fetus was removed. Catheter placement was confirmed at autopsy, and the fetus was weighed.
Measurements. Pulmonary and systemic arterial blood pressures and right and left atrial pressures were measured by Statham P23Db pressure transducers (Statham Instruments, Hato Rey, Puerto Rico). Mean pressures were obtained by electrical integration. Heart rate was measured by a cardiotachometer triggered from the phasic systemic arterial pressure pulse wave. Left pulmonary arterial blood flow was measured by a transit time flow meter (Transonic Systems, Inc.). All hemodynamic variables were recorded continuously on a Gould multichannel electrostatic recorder (Gould Inc., Cleveland, OH). Systemic arterial (descending aortic) blood gases and pH were measured on a Coming 158 pH/blood gas analyzer (Corning Medical and Scientific, Medfield, MA). All fetal pressures were corrected to amniotic fluid pressure as a zero reference level. Left pulmonary arterial vascular resistance was calculated as follows: (mean pulmonary arterial blood pressure -mean left atrial pressure) + (left pulmonary arterial blood flow/kg of fetal weight).
Statistical analysis. Means + SD were calculated for the hemodynamic variables, systemic arterial blood gases, and pH during all experimental conditions. The effects of each vasoactive agent (ET-I, BQ 123, 4 Ala ET-1, sodium bicarbonate, cromakalim, and glibenclamide) on these variables were compared with their previous steady state (baseline) condition by the paired t test.
Changes in left pulmonary arterial blood flow and left pulmonary vascular resistance were compared by the Wilcoxon Signed Rank test because of their wide SD. The absolute changes in left pulmonary vascular resistance and left pulmonary arterial blood flow and the percent change in mean pulmonary arterial blood pressure produced by left pulmonary artery injections of ET-I and 4 Ala ET-I were compared with the respective changes produced by inferior vena cava injections of ET-I and 4 Ala ET-1. Similarly, changes in response to injections of ET-I or cromakalim before or during glibenclamide infusion were assessed by the Wilcoxon Signed Rank test. Baseline measurements before each intervention were compared by analysis of variance for repeated measures and were not different. For all evaluations, p < 0.05 was considered statistically significant.
RESULTS
Fetal baseline arterial blood gases and pH were measured before starting each study and were within the normal range for the laboratory (Table 1) .
ET-I and 4 Ala ET-I injections. Injections of ET-I into the left pulmonary artery increased left pulmonary arterial blood flow and decreased left pulmonary vascular resistance (Table 1) . Mean pulmonary and systemic arterial blood pressures were unchanged. Injections of ET-I into the inferior vena cava increased left pulmonary arterial blood flow but did not significantly change left pulmonary vascular resistance or mean pulmonary and systemic arterial blood pressures (Fig. l, Table l) . Injections of ET-1 into the left pulmonary artery produced a greater decrease in left pulmonary vascular resistance than injections into the inferior vena cava (5.17 f 7.12 versus 1.26 + 2.14 mm Hg/mL/kg/min, p < 0.05). The increase in left pulmonary Injections of 4 Ala ET-I into the left pulmonary artery produced a greater increase in left pulmonary arterial blood flow than did injections of ET-1 into the left pulmonary artery (60.8 + 28.6 versus 53.7 +. 34.5 kg/mL/min, p < 0.05). The injections of 0.9% saline and 2% DMSO as controls had no hemodynamic effects.
Infusions of BQ 123 into the left pulmonary artery. The infusion of BQ 123 into the left pulmonary artery increased left pulmonary arterial blood flow and decreased left pulmonary vascular resistance at both 5 and 10 min after the start of the infusion (Fig. 2, Table 2 ). Mean pulmonary and systemic arterial blood pressures were unchanged. The infusion of sodium bicarbonate into the left pulmonary artery did not change any of the hemodynamic variables.
ET-I injections before and during glibenclamide infusion. In the five animals studied on the second day, before the infusion of glibenclamide, ET-I increased left pulmonary arterial blood flow and decreased left pulmonary vascular resistance as well as mean pulmonary and systemic arterial blood pressures (Fig. 3,  Table 3 ). Similarly, before the infusion of glibenclamide, cromakalim increased left pulmonary arterial blood flow and decreased left pulmonary vascular resistance and mean pulmonary arterial blood pressure. Systemic arterial blood pressure was unchanged. The animals were allowed to rest and the hemodynamic variables returned to baseline levels before an infusion of glibenclamide was started (data not shown).
Before the ET-I or cromakalim injections were repeated, infusion of glibenclamide into the left pulmonary artery for 15 min increased left pulmonary arterial blood flow (from 34.1 + 50.0 to 58.0 * 53.5 mL/kg/min, p c 0.05) and decreased left pulmonary vascular resistance (from 4.88 ? 5.88 to 1.60 + 1.14 mm Hg/mL/kg/min, p < 0.05) but did not change mean pulmonary arterial blood pressure. The remaining hemodynamic variables did not change, except for systemic arterial PO*, which increased (from 2.21 + 0.60 to 2.64 + 0.39 kPa, p < 0.05).
After the infusion of glibenclamide, ET-I still increased left pulmonary arterial blood flow and decreased left pulmonary vascular resistance (Table 3) . Mean pulmonary and systemic arterial blood pressures were unchanged. Although cromakalim also still increased left pulmonary arterial blood flow, left pulmonary vascular resistance and mean pulmonary and systemic arterial blood pressures were unchanged. However, the absolute increase in left pulmonary arterial blood flow produced by both ET-I and cromakalim was significantly attenuated after the infusion of glibenclamide (Fig. 3, Table 3 ). Glibenclamide attenuated the absolute decrease in left pulmonary vascular resistance induced by cromakalim ( p < 0.05) but not that produced by ET-I .
DISCUSSION
This study, in chronically instrumented late gestational age fetal sheep in utero, shows that ET-I is a potent pulmonary vasodilator and that ET receptor activation partly regulates fetal pulmonary vascular tone. Injections of exogenous ET-I into the left pulmonary artery and inferior vena cava produced potent increases in pulmonary blood flow in the physiologically high pulmonary vascular tone of the fetus. The infusion of BQ 123, an ET, receptor antagonist, produced modest increases in left pulmonary blood flow, and the injection of 4 Ala ET-1, an ETb receptor agonist, produced potent pulmonary vasodilation. Glibenclamide, an ATP-dependent potassium channel blocker, attenuated the pulmonary vasodilation produced by ET-I, suggesting that this effect is partly mediated by ATP-dependent potassium channels. Although the effects of exogenous ET-I have been reported previously ( 1, 2, 17), the role of endogenous ET-I in regulating fetal pulmonary vascular tone has not been addressed. Similarly, the role of endothelin receptor subtypes in the regulation of fetal pulmonary vascular tone has not been reported previously.
Using a preparation that completely removes any artifactual changes in pulmonary blood flow caused by ductus arteriosus constriction, this study confirms previous observations that show ET-I is a pulmonary vasodilator in the fetus (I, 2, 17). In our study, injections of ET-I into both the left pulmonary artery and the inferior vena cava increased left pulmonary blood flow. However, injections of ET-I into the left pulmonary artery produced a greater increase than injections into the inferior vena cava. There are several possible explanations for this difference. One is that the injection of ET-I into the inferior vena cava is diluted before it reaches the pulmonary circulation so that the effective concentration is less than that of an injection into the left pulmonary artery. Another explanation is that some of the ET-I from the injection into the inferior vena cava is diverted into the systemic circulation through either the foramen ovale, the ductus arteriosus, or both.
In contrast to the present study, a previous study in sheep of similar gestational ages ( 124-142 d) showed that infusions of ET-1 into the vena cava increased pulmonary arterial pressure and pulmonary vascular resistance (2) . Likely explanations for these differences include the dosage used, the method of administration, and, more importantly, the status of the ductus arteriosus, as indicated above. Recent in vitro data suggest that ET-I is a potent constrictor of the ductus arteriosus (20, 21). Therefore, acute constriction of the ductus arteriosus in response to ET-I may contribute to the increase in pulmonary vascular resistance, as has been described previously in studies that have produced ductus arteriosus constriction by different means (22,23). In our study, injection of ET-I into the inferior vena cava increased mean pulmonary and systemic arterial blood pressure and calculated left pulmonary vascular resistance in one animal; this may have reflected incomplete formalinization of the ductus arteriosus in that particular fetus. Although not apparent, differences in basal pulmonary vascular tone might also partly explain the different results.
From this study we conclude that the vasoconstricting effects of ET-I, mediated by ET, receptors, contribute to the physiologically high pulmonary vascular tone of the fetus. We have previously shown in newborn lambs that BQ 123 is a selective inhibitor of ET-I-induced pulmonary vasoconstriction and does not alter ET-1 -induced pulmonary vasodilation (8) . BQ 123 has also been shown to inhibit ET-I-induced pulmonary vasoconstriction in isolated adult rat lungs and main pulmonary artery rings (6) . The infusion of BQ 123 into the left pulmonary artery in this study produced only a small increase in left pulmonary arterial blood flow and a small decrease in left pulmonary vascular resistance. The modest effect of BQ 123 on the pulmonary vascular tone is also transient, inasmuch as the effects rapidly decreased within 10 min. One can speculate that there are relatively few ET, receptors in the fetal pulmonary circulation or that either receptor or postreceptor mechanisms that mediate the effects of ET-I are immature. This would be consistent with our earlier observations that a very large dose of ET-1 is required to activate ET, receptors to increase resting pulmonary vascular tone in newborn lambs (4, 8) .
Activation of ETb vasodilator receptors by 4 Ala ET-I, a selective ETb agonist, produced potent pulmonary vasodilation. The ETb agonists are linear polypeptide analogs of the native ET-I polypeptide. There is an Ala substitution at the 1, 3, 1 1, and 15 amino acid sequence of the native ET-I polypeptide in 4 Ala ET-1 (10, 1 1). We have previously shown in newborn lambs that 4 Ala ET-I is a selective pulmonary ET, vasodilator agonist during pulmonary hypertension (18). In this study, the marked decrease in pulmonary vascular tone produced by 4 Ala ET-I would suggest that the majority of the ET-I receptors that are of physiologic importance in the near-term fetal pulmonary circulation are ETb vasodilator receptors. One can speculate that if there is an abundance of ETb vasodilator receptors in the fetal circulation they may play an important role in the transitional circulation of the newborn and in the normal decrease in pulmonary vascular tone that occurs at birth.
The increase in left pulmonary arterial blood flow produced by ET-I in fetuses is mediated partly by ATP-dependent potassium channels. We and others have previously shown in newborn lambs and in other species that ET-I and ETb agonist-induced pulmonary vasodilation is mediated by the release of EDNO or by activation of ATP-dependent potassium channels (3, 4, (15) (16) (17) . As is true in newborn lambs, the pulmonary vasodilating effects of ET-I in fetal sheep are mediated by the release of EDNO ( 17). Because the potassium channel blocker glibenclamide did not completely inhibit the effects of ET-1, we presume that part of the pulmonary vasodilation produced by ET-I in our study is also mediated by EDNO release. In our study, attenuation of the decrease in left pulmonary vascular resistance produced by ET-I during the infusion of glibenclamide did not reach statistical significance, because in one fetus the decrease in pulmonary arterial blood pressure, and therefore the calculated vascular resistance, was greater after the glibenclamide infusion. However, we still can assume that ATP-dependent potassium channels, as they do in newborn lambs, play a physiologic role in the pulmonary vasodilation and flow effects of ET-I in the fetus.
Although there were decreases in pulmonary arterial blood pressure, ET-I and 4 Ala ET-I did not markedly change systemic arterial blood pressure. We previously showed that ET-I increased systemic arterial blood pressure, whereas 4 Ala ET-I did not change systemic arterial blood pressure in newborn lambs (1 8). A possible reason why ET-I did not affect the fetal systemic circulation is that the amount of ET-I reaching the systemic circulation may have been very small. The small, transient decrease in systemic arterial blood pressure produced by ET-I may be secondary to blood flow diversion from the ductus arteriosus to the pulmonary circulation during pulmonary vasodilation. This is in contrast to the finding that infusions of ET-I into the inferior vena cava increased systemic arterial blood pressure (2) . The difference may be that the cumulative dose of ET-I was greater in that study than in our study, and therefore ET-I is able to cause systemic vasoconstriction. In summary, ET-I and its receptors affect basal fetal pulmonary vascular tone, and both vasoconstrictor and vasodilator receptor subtypes and their mechanisms for producing an effect are present in late-gestation fetal lambs. ET, receptors, which mediate ET-I-induced vasoconstriction, contribute a small part to maintaining the high fetal pulmonary vascular tone. However, ET-I, through the activation of ETb receptors, markedly decreases fetal pulmonary vascular tone. In healthy newborns, circulating concentrations of ET-I are higher than in adults (24). From our studv and from ~revious studies. it seems that the role of ET-I in thedperinatal pe'riod is to produce pulmonary vasodilation of the transitional circulation through secondary mechanisms such as EDNO production or ATP-dependent potassium channel activation. Aberrations of ET-I receptors in utero may play a role in the development of pulmonary hypertensive disorders in infancy. Additional studies on the role of ET-I and its receptors in the normal and abnormal transitional circulation may provide potential new therapies for disorders such as persistent pulmonary hypertension of the neonate.
